Biopharmaceutical company developing muscle activators as potential treatments for neuromuscular and other diseases.
Cytokinetics, Incorporated is a leading biopharmaceutical company in the late-stage development phase, dedicated to discovering, developing, and commercializing innovative treatments targeting debilitating diseases through muscle activators and inhibitors. Founded in 1997 and headquartered in South San Francisco, California, the company specializes in advancing small molecule drug candidates engineered to impact muscle function and contractility.
The company's diverse pipeline includes omecamtiv mecarbil, a pioneering cardiac myosin activator currently undergoing Phase III clinical trials for heart failure patients. Additionally, Cytokinetics is progressing reldesemtiv, a skeletal muscle troponin activator, through Phase III clinical trials aimed at treating conditions such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).
Cytokinetics continues to expand its portfolio with promising candidates like CK-136, a novel cardiac troponin activator in Phase I clinical trials, and aficamten, a cardiac myosin inhibitor also in Phase III clinical trials for symptomatic obstructive hypertrophic cardiomyopathy. Furthermore, the company is advancing CK-3772271, a small molecule cardiac myosin inhibitor currently undergoing Phase I clinical evaluation.
With a strategic alliance with Astellas Pharma Inc., Cytokinetics leverages collaborative efforts to enhance research, development, and commercialization capabilities, underscoring its commitment to pioneering therapies that address significant unmet medical needs in muscle-related diseases. The company remains dedicated to advancing scientific innovation and improving patient outcomes globally.